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CASE REPORTSEarly failures of Trifecta aortic bioprosthesisSalvatore Campisi, MD,a Lionel Camilleri, MD, PhD,b Andrea Innorta, MD,b and
Kasra Azarnoush, MD, PhD,b St Etienne and Clermont-Ferrand, FranceThe Trifecta valve (St Jude Medical, Inc, St Paul, Minn) is a
third-generation, stented bioprosthesis designed for
supra-annular implantation in the aortic position. It is a
bovine bioprosthesis manufactured from 3 pericardial
leaflets externally mounted on a titanium stent. The
polyester components of the bioprosthesis are covered
with porcine pericardial tissue.
The onset of structural deterioration as a cause of
reoperation has scarcely been reported in international
published studies.1CASE 1
A 78-year-old woman had undergone combined aortic
valve replacement and septal myomectomy (implantation
of a 19-mm St Jude Trifecta valve) for severe aortic
valve stenosis (mean transvalvular gradient, 38 mm Hg;
estimated aortic valve orifice area, 0.8 cm2) and hypertro-
phic cardiomyopathy.
The postoperative period was complicated by atrial
fibrillation associated with a third-degree atrioventricular
block that required pacemaker implantation. Postoperative
transthoracic echocardiography showed a left ventricular
ejection fraction of 70% and a normally functioning aortic
bioprosthesis (transvalvular mean gradient, 10 mm Hg;
effective orifice area, 1.43 cm2) without any signs of
paravalvular leak. However, 3 months later, the patient
was readmitted for asthenia associated with left ventricular
heart failure.
The clinical examination revealed an aortic diastolic
murmur. Multiple blood cultures collected at admission
failed to detect any microorganism. Transthoracic
echocardiography showed severe intraprosthetic, aortic
regurgitation with a normal left ventricular ejection fraction
(65%). In addition, neither vegetations nor abscesses were
detected. Therefore, structural dysfunction of the prosthesis
itself was suspected, although no signs of paravalvular
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The Journal of Thoracic and Carthat the noncoronary leaflet of the bioprosthesis was
tightly attached to the corresponding Valsalva sinus;
consequently, the remaining part of the noncoronary leaflet
had restricted movement, leading to incomplete leaflet
coaptation (Figure 1).
The valve was gently detached from the aortic wall and
replaced with a 19-mm Carpentier Edwards Perimount
Magna Ease bioprosthesis (Edwards Lifesciences,
Irvine, Calif). The patient had an uneventful postoperative
recovery.
On histopathologic examination, neither specific signs of
inflammatory processes nor pannus were found. The results
of the microscopic investigation indicated that all 3 cusps
had fibrotic tissue. The results of additional bacteriologic
investigations were all negative.CASE 2
During preoperative screening for hip surgery, a 74-year-
old male patient was diagnosed with coronary artery disease
associated with aortic stenosis. On the preoperative
echocardiographic scan, the mean aortic valve gradient was
estimated at 52 mm Hg, with an estimated aortic valve
orifice area of 0.7 cm2. He underwent aortic valve
replacement by implantation of a 23-mm St Jude Trifecta
valve (St Jude Medical, Inc) and coronary artery bypass
grafting.
The postoperative period was uneventful. The postopera-
tive transvalvular gradient was 7 mm Hg, and the effective
area of the prosthetic valve was 2.3 cm2.
Eight months later, he underwent radiofrequency catheter
ablation for atrial fibrillation without any complications.
However, he was readmitted to the intensive care unit 1
month later because of left ventricular heart failure that
required diuretics and inotrope support. The clinical
examination found an aortic regurgitation murmur, and
echocardiography confirmed the presence of massive
intraprosthetic aortic regurgitation without vegetations.
On reoperation, a partial tear on the stent between the left
coronary and the noncoronary cusps of the bioprosthesis
was found (Figure 2). The Trifecta bioprosthesis was
replaced with a 23-mm Perimount Magna Ease Carpentier
Edwards (Edwards Lifesciences).
The patient did not experience any postoperative compli-
cations. The results from the bacteriologic investigations
were all negative. The bioprosthesis was sent to the
manufacturer for additional analysis. Macroscopic patho-
logic analysis found complete cusp tissue detachment
from the stent between the 2 cusps. The pericardialdiovascular Surgery c Volume 148, Number 1 e133
FIGURE 1. Leaflet and commissural-damaged pericardial bioprosthesis.
FIGURE 2. Partial tear of the suture zone between the pericardial leaflet
and the stent of the bioprosthesis.
Case Reportstissue did not show any visible calcifications. Microscopic
analysis did not find any other abnormality on either the
internal or external side.
DISCUSSION
The new aortic St Jude Trifecta tissue valve has a unique
valve design that opens more fully and efficiently, such that
it maximizes transvalvular flow and offers excellent
hemodynamic performance. These characteristics have
helped make it very attractive for aortic valve replacement,
especially for a small aortic annulus.2,3 However, all
theoretical advantages conferred by new devices must be
measured in terms of hemodynamic performance and
durability.4
Since its introduction in clinical practice in 2009, few
cases of structural deterioration have been reported in
published studies.1,5,6
In our first patient, during the first surgery the aortotomy
was performed very low and extended near the aortic
annulus in the noncoronary sinus. We hypothesized that
the reaction to the polypropylene suturematerial at the aortic
suture line might have favored cusp attachment to the aortic
wall by a fibrotic process. This phenomenon of foreign body
reaction around polypropylene sutures is well known and
described in the published studies.7,8 A predisposing factor
was the small aortic root, resulting in the close proximity
between the bioprosthesis and aortic suture line.
It is probable that the specific design of the Trifecta valve,
with 3 leaflets externally mounted on a stent, is responsible
for the excellent hemodynamic performance. However, that
design has also predisposed it, in small aortic roots, to
incidents such as the case we have reported.
In our second patient, a peculiar pericardial fragility
could explain the dysfunction, although additional
investigations performed by the manufacturer did not
show any specific pericardial vulnerability. One hypothesis
is to compare this new device to the Ionescu-Shiley valve,
which has a very similar design and was plagued with
cusp tears similar to that described.9,10 Nevertheless,
tissue valves from any manufacturer will occasionallye134 The Journal of Thoracic and Cardiovascular Surdemonstrate early failure for unknown reasons. Perhaps
that was the case for the second patient in the present
study, but it is not obvious that the tear resulted from a
design flaw.
These complications did not discourage the implantation
of Trifecta valves in our university hospital. However, in the
case of small calcified aortic roots, some precautions must
be taken. First, one should not extend the aortotomy too
low, and a stented bioprosthesis with pericardial leaflets
fixed inside the stent should be used.References
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